MMWR. Morbidity and mortality weekly report

Use and Changes in Glucagon-Like Peptide-1 Medicine Use Among Adults in the United States, 2025

Updated

Abstract

Approximately 10% of U.S. adults reported taking a GLP-1 medication in the past year.

  • One in five GLP-1 users reported using a compounded version of the medication, which is not FDA-reviewed.
  • Nearly two in five GLP-1 users adjusted their medication use, often due to cost and availability issues.
  • Modifications in GLP-1 medication use were particularly prevalent among younger adults.
  • The widespread use of GLP-1 medications indicates their growing role in treating chronic diseases.
  • Understanding real-world adjustments in medication use is important for assessing safety and effectiveness.

Simplified

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free